… In summary, using convalescent sera from individuals infected in wave 1, we showed that
cross-neutralizing antibodies are detected up to 10 months POS in some individuals. Infection …

… as SARS-CoV-1, shows that such convalescent sera contain … antibody for SARS-CoV-2 are
human convalescent sera from … use is that found in human convalescent sera (Figure 1). As …

… sera from individuals with different levels of immunity. We included samples from individuals
who had recovered from SARS-CoV-2 infection (convalescent … 10), convalescent individuals …

… Neutralization of B.1.617.2 by convalescent serum We measured neutralization of B.1.617.2
native virus on the same set of United Kingdom convalescent samples taken early during …

… comparison to convalescent sera. … sera and convalescent sera have a higher titer of
spike-RBD-specific antibodies and neutralizing antibodies as compared to the CVnCoV-elicited sera…

… (WT) and mutant Spike proteins of SARS-CoV-2 were codon-optimized and synthesized
by … of SARS-CoV-2. Then, we assessed the neutralizing efficacy of 40 convalescent serum …

… with four pairs of acute and convalescent sera from recovered SARS cases. We correlated
… in vitro SARS-CoV neutralizing activity of the samples. We found that convalescent sera with …

… serum is less effective at neutralizing B.1.1.7 and B.1.351 than early lineage SARS-CoV-2,
and that convalescent serum … neutralized compared to early lineage SARS-CoV-2. Further, …

… Huge strides have been made in the understanding of SARSCoV-2 over the last year, which
… assays on convalescent and vaccine serum revealed that the B.1.1.7 virus required higher …

… -2 versus USA-WA1/2020 for vaccinated (3·4-fold) and convalescent … the convalescent
sera. These data suggest that the single E484K mutation in the RBD affects the binding of serum …